Abstracts tagged "Hydroxychloroquine"

Abstract Number: 606 • 2013 ACR/ARHP Annual Meeting
Characteristics Of Lupus Nephritis: Data From a Large Multicenter Registry Of Patients With Systemic Lupus Erythematosus
Diane L. Kamen¹, Graciela S. Alarcon², Jill P. Buyon³, Mary Anne Dooley⁴, Richard A. Furie⁵, David S. Pisetsky⁶ and Tammy O. Utset⁷, ¹Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ²Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ⁶Department of Medicine, Duke University Medical Center, Durham, NC, ⁷Rheumatology, University of Chicago Medical Center, Chicago, IL
Background/Purpose: Renal disease is strongly associated with morbidity and mortality among SLE patients. We utilized the Lupus Clinical Trials Consortium, Inc. longitudinal registry of SLE…
Abstract Number: 2569 • 2012 ACR/ARHP Annual Meeting
Hydroxychloroquine Reduces Thrombosis in Systemic Lupus Erythematosus, Particularly in Antiphospholipid Positive Patients
Genevieve Law¹, Laurence S. Magder², Hong Fang³ and Michelle Petri³, ¹Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Past studies, mostly cross-sectional, have found a reduction in thrombosis in systemic lupus erythematosus (SLE) patients taking hydroxychloroquine (HCQ). We examined the relationship between…
Abstract Number: 2482 • 2012 ACR/ARHP Annual Meeting
Hydroxychloroquine Has Lipid-Lowering Effects in US Veterans with Rheumatoid Arthritis
Nicole A. Kieffer¹, Gail S. Kerr², J. Steuart Richards³, Lisa A. Davis⁴, Liron Caplan⁵, Jeffrey Huang⁶, Grant W. Cannon⁷, Harlan Sayles⁸ and Kaleb Michaud⁹, ¹Division of Rheumatology, Georgetown University, Washington, DC, ²Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ³Rheumatology, Washington DC VA and Georgetown University, Washington, DC, ⁴Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ⁵Div of Rheumatology, Denver VA and Univ of Colorado School of Medicine, Aurora, CO, ⁶Rheumatology, Washington DC VA and Howard University Hospital, Washington, DC, ⁷Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, ⁸Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁹Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Recent data report significant decreases in low-density lipoprotein (LDL) and total cholesterol (TC) levels in predominantly female Caucasian rheumatoid arthritis (RA) patients treated with…
Abstract Number: 1933 • 2012 ACR/ARHP Annual Meeting
Incidence and Early Detection of Retinal Toxicity in Patients Treated with Chloroquine and Hydroxichloroquine in Rheumatology Practice
Sandra Soro Marin¹, Ana del Carmen Haro Martínez¹, Deseada Palma Sanchez¹, María del Rocío Gonzalez Molina¹, Marta Mayor Gonzalez² and Elena Rubio Velazquez³, ¹Rheumatology, Rafael Mendez Hospital, Spain., Lorca (Murcia), Spain, ²Rheumatology, Rafael Mendez Hospital, Lorca (Murcia), Spain, ³Ophthalmology, Rafael Mendez Hospital, Lorca (Murcia)
Background/Purpose: The antimalarial drugs are considered safe and well tolerated, with low risk of side effects. Hydroxychloroquine is considered safer but less effective than chloroquine,…
Abstract Number: 635 • 2012 ACR/ARHP Annual Meeting
Elevated Transglutaminase Levels On Microparticles From Systemic Lupus Erythematosus Patients
Leslie Harris¹, Ratnesh Chopra¹, Ann K. Rosenthal² and Mary E. Cronin³, ¹Division of Rheumatology/Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, ²Div of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ³Rheumatology, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Systemic Lupus Erythematosus ( SLE) is characterized by the formation of autoantibodies, and over-exuberant antigen presentation may account for some of this pathology .…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].